Citations

Clear

3138 citation(s) found for "Smith, AM".

Correlation of the Sinonasal Outcome Test‐22 With the University of Washington Quality of Life in Assessing Quality of Life in Sinonasal Malignancy Utilizing a Multicenter Prospective Observational Cohort Registry
Fleseriu, Cara M. , Beswick, Daniel M. , Maoz, Sabrina L. , Hwang, Peter H. , Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Traylor, Katie , Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Patel, Zara M. , Smith, Timothy L. , Wang, Marilene B. , Wang, Eric W , Beswick, Daniel , Maoz, Sabrina L , Hwang, Peter H , Humphreys, Ian M , Jafari, Aria , Kingdom, Todd T , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Choby, Garret , Kuan, Edward C , Adappa, Nithin D. , Geltzeiler, Mathew , Abuzeid, Waleed M. , Pinheiro‐Neto, Carlos , Le, Christopher H. , Lee, Jivianne K., Nayak, Jayakar V. , John, Maie A. St. , Suh, Jeffrey D. , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | January 6, 2025 | Volume: 15 | Issue: 4 | Pages: 451-454

10.1002/alr.23522 | PMID 39761380 Get It

Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine
Yang, Seonkyeong , Orlova, Yulia , Smith, Steven M. , Guo, Yi , Chapin, Benjamin A. , Wilson, Debbie L. , Smith, Steven M , Park, Haesuk , Lo‐Ciganic, Wei‐Hsuan

Mayo Clinic

JAMA Neurology | January 6, 2025 | Volume: 82 | Issue: 2 | Pages: 132

10.1001/jamaneurol.2024.4537 | PMID 39761027 Get It

Importance Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP mAbs) offer effective migraine-specific preventive treatment. However, concerns exist about their potential cardiovascular risks due to CGRP blockade. Objective To compare the incidence of cardiovascular disease (CVD) between Medicare beneficiaries with migraine who initiated anti-CGRP-mAbs vs onabotulinumtoxinA in the US. Design, Setting, and Participants This retrospective, sequential cohort study was conducted among a nationally representative population-based sample of Medicare claims from May 2018 through December 2020. Data analysis was performed from August to December 2023. This study included fee-for-service Medicare beneficiaries aged 18 years or older with migraine who initiated either anti-CGRP mAbs or onabotulinumtoxinA. Beneficiaries who had a history of myocardial infarction (MI), stroke, cluster headache, malignant cancer, or hospice service within a 1-year baseline period prior to treatment initiation were excluded. To minimize channeling bias from new drug introductions and time-related bias due to the COVID-19 pandemic, 5 cohorts were established, representing sequential 6-month calendar intervals based on the initial prescription or date of index anti-CGRP mAbs or onabotulinumtoxinA use. Exposure Anti-CGRP mAbs vs onabotulinumtoxinA. Main Outcomes and Measures The primary outcome was time to first MI or stroke. Secondary outcomes included hypertensive crisis, peripheral revascularization, and Raynaud phenomenon. The inverse probability of treatment-weighted Cox proportional hazards models were used to compare outcomes between the 2 treatment groups. Results Among 266 848 eligible patients with migraine, 5153 patients initiated anti-CGRP mAbs (mean [SD] age, 57.8 [14.0] years; 4308 female patients [83.6%]) and 4000 patients initiated onabotulinumtoxinA (mean [SD] age, 61.9 [13.7] years; 3353 female patients [83.8%]). Use of anti-CGRP mAbs was not associated with an increased risk of composite CVD events (adjusted hazard ratio [aHR], 0.88; 95% CI, 0.44-1.77), hypertensive crisis (aHR, 0.46; 95% CI, 0.14-1.55), peripheral revascularization (aHR, 1.50; 95% CI, 0.48-4.73), or Raynaud phenomenon (aHR, 0.75; 95% CI, 0.45-1.24) compared with onabotulinumtoxinA. Subgroup analyses by age group and presence of established non-MI or stroke CVD showed similar findings. Conclusions and Relevance In this cohort study, despite initial concerns regarding the cardiovascular effects of CGRP blockade, anti-CGRP mAbs were not associated with an increased risk of CVD compared with onabotulinumtoxinA among adult Medicare beneficiaries with migraine, who were predominantly older adults or individuals with disability. Future studies with longer follow-up periods and in other populations are needed to confirm these findings.
Severe Non–Donor-Derived Lymphocytic Choriomeningitis Virus Infection in 2 Solid Organ Transplant Recipients
Sayyad, Leanna , Smith, K. L. , Sadigh, Katrin S. , Cossaboom, Caitlin M. , Choi, Mary J. , Whitmer, Shannon , Cannon, Debi , Krapiunaya, Inna , Morales-Betoulle, Maria , Annambhotla, Pallavi , Basavaraju, Sridhar V. , Ruberto, Irene, Kretschmer, Melissa , Gutiérrez, Nubia Silva, Zabel, Karen, Austin, Connie, Sandoval, Edith, Servellita, Venice , Foresythe, Abiodun, Sumimoto, Nanami, Aqel, Bashar , Khamash, Hasan , Jaramillo, Andrés , Grill, Marie , Montgomery, Joel M. , Shoemaker, Trevor , Vikram, Holenarasipur R. , Sayyad, Leanna E , Smith, Kami L , Khamash, Hassan , Jadlowiec, Caroline , Grys, Thomas E , Jaramillo, Andres , Grill, Marie F , Montgomery, Joel M , Shoemaker, Trevor , Klena, John D , Chiu, Charles , Vikram, Holenarasipur R. , Gutierrez, Nalleli, Sandoval, Edith, Aqel, Bashar A. , Jadlowiec, Caroline C. , Grys, Thomas E. , Chiu, Charles Y.

Mayo Clinic

Open Forum Infectious Diseases | January 3, 2025 | Volume: 12 | Issue: 2 | Pages: No page available

10.1093/ofid/ofaf002 | PMID 39896983 Get It

Abstract Background Lymphocytic choriomeningitis virus (LCMV) infection in immunocompromised hosts can result in disseminated disease, meningoencephalitis, and death. Published cases in transplant recipients have been traced to transmission from infected donors. We report 2 cases of serious, non–donor-derived LCMV infection in solid organ transplant recipients. Methods Initial identification of LCMV infection was done by using metagenomic next-generation sequencing (mNGS). Subsequent evaluations and confirmatory testing involved molecular diagnostics, serology, and phylogenetic analysis. A detailed epidemiologic investigation was conducted. Results LCMV was detected by mNGS in 2 solid organ transplant recipients from distinct donors. A heart transplant recipient (from donor 1) died of progressive, disseminated LCMV infection, while a kidney transplant recipient (from donor 2) with LCMV meningoencephalitis survived. A multistate laboratory and epidemiologic investigation of both donors and all their organ recipients was initiated. Postmortem samples were obtained from both donors, and pretransplant and/or posttransplant samples were obtained from 5 of the 6 organ recipients. mNGS, serologic, and real-time reverse-transcription polymerase chain reaction testing confirmed LCMV infection in both solid organ transplant recipients. Epidemiologic investigation revealed significant pretransplant rodent exposures for both LCMV-infected recipients. Laboratory studies for the other organ recipients from both donors were negative for LCMV infection. Conclusions Our investigations suggest that LCMV infection in 2 solid organ transplant recipients originated from rodent exposure preceding transplantation and were not donor derived. Although uncommon, healthcare providers should be aware of LCMV-associated serious and life-threatening illness in immunocompromised hosts. Diagnostic modalities are limited to reference laboratories.
A harmonized memory composite score for cross‐cohort Alzheimer’s disease and related dementia research: development and validation
Gross, Alden L. , Casaletto, Kaitlin B. , Chatterjee, Ankita , Albert, Marilyn S. , Apostolova, Liana G. , Boersema, Brooke, Boxer, Adam L., Clark, Lindsay R. , Eloyan, Ani , Farias, Sarah Tomaszewski , Hammers, Dustin B. , Wise, Amy B. , Yballa, Claire, Hampstead, Benjamin M. , Rascovsky, Katya, Ringman, John M. , Rosen, Howard J., Salmon, David P. , Kramer, Joel H. , Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Gaynor, Leslie S. , Paolillo, Emily W. , Boxer, Adam L. , Boeve, Bradley F. , Joie, Renaud La , Gonzales, Mitzi M. , Hammers, Dustin B , Cobigo, Yann , Schonhaut, Daniel R. , Mechanic-Hamilton, Dawn J. , Miller, Bruce L. , Rabinovici, Gil D. , Ryman, Sephira G. , Smith, Glenn E. , DeCarli, Charles

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.093383 Get It

AbstractBackgroundThe Uniform Data Set (UDS) neuropsychological battery, administered across Alzheimer’s Disease Centers (ADC), includes memory tests but lacks a list‐learning paradigm. ADCs often supplement the UDS with their own preferred list‐learning task. Given the importance of list‐learning for characterizing memory, we aimed to develop a harmonized memory score that incorporates UDS memory tests while allowing centers to contribute differing list‐learning tasks.MethodWe applied item‐banking confirmatory factor analysis to develop a composite memory score in 5,287 participants (mean age 67.1; SD = 12.2) recruited through 18 ADCs and four consortia (DiverseVCID, MarkVCID, ALLFTD, LEADS) who completed UDS memory tasks (used as linking‐items) and one of five list‐learning tasks. All analyses used linear regression. We tested whether memory scores were affected by which list‐learning task was administered. To assess construct validity, we tested associations of memory scores with demographics, disease severity (CDR Box Score), an independent memory task (TabCAT Favorites, n = 675), and hippocampal volume (n = 811). We compared performances between cognitively unimpaired (n = 279), AD‐biomarker+ MCI (n = 26), and AD‐biomarker+ dementia (n = 98). In a subsample with amyloid‐ and tau‐PET (n = 49), we compared memory scores from participants with positive vs negative scans determined using established quantitative cutoffs.ResultModel fit indices were excellent (e.g., CFI = 0.998) and factor loadings were strong (0.43‐0.93). Differences in list‐learning task had a negligible effect on scores (average Cohen’s d = 0.11). Higher memory scores were significantly (p’s<.001) correlated with younger age (β = ‐0.18), lower CDR Box Scores (β = ‐0.63), female sex (β = 0.12), higher education (β = 0.19), larger hippocampal volume (β = 0.42), and an independent memory task (β = 0.71, p<0.001). The memory composite declined in a stepwise fashion by diagnosis (cognitively unimpaired>MCI>AD dementia, p<0.001). On average, amyloid‐PET positivity was associated with lower composite scores, but was not statistically significant (β = ‐0.34; p = 0.25; d = 0.40). Tau‐PET positivity was associated with worse performance, demonstrating a large effect size (β = ‐0.75; p<0.002; d = 0.91).ConclusionThe harmonized memory score developed in a large national sample was stable regardless of contributing list‐learning task and its validity for cross‐cohort ADRD research is supported by expected associations with demographics, clinical measures, and Alzheimer’s biomarkers. A processing script will be made available to enhance cross‐cohort ADRD research.
A Pilot Study to evaluate feasibility of a teleneuropsychological protocol in older adults in Panama and Florida
Mejía, Luis Guillermo Santos , Pérez-Lao, Ámbar , Oviedo, Diana C. , Britton, Gabrielle B. , Smith, Glenn E.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.090965 Get It

AbstractBackgroundThe use of videoconference platforms for neuropsychological assessment was not as common among mental health practitioners before the COVID‐19 pandemic. However, due to lockdowns and quarantines worldwide, mental health professionals had to find a feasible alternative and shift to virtual evaluations. This increased the use of teleneuropsychology in both at a clinical and research level. Studies conducted during the pandemic provided evidence of the feasibility of virtual assessments, but data from low‐and middle‐income countries is scarce and conclusions from studies in other regions cannot be generalized. The objective of this study is to develop and apply a teleneuropsychological assessment battery on a group of elderly adults in Panama and Hispanics living in the United States.MethodThis is a multicenter study that will gather data from a Panamanian Cohort parallel to the current Florida‐based study Development and Validation of TeleNeuropsychology Normative Data for Older Adults (FLOAT). So far 80 participants over 50 years old have been assessed in Panama and Florida. Inclusion criteria includes passing a screening with TICS‐M for low risk of developing dementia and having basic knowledge and accessibility of electronic devices. Researchers contact potential participants through calls and WhatsApp chats to explain the study and obtain informed consent. Participants are then screened to see if they are eligible to be assessed through the video conference platform. Participants must complete the teleneuropsychological assessment battery from the National Alzheimer’s Coordinating Center (NACC), and different questionnaires to provide socio‐demographic and functional data. All information is gathered with the REDCap platform.ResultOne hundred participants will be assessed with a teleneuropsychology protocol in each cohort. Once all data is collected, it will be analyzed with multivariate statistics methods. We expect to describe the protocol’s feasibility assessing older adults in both locations.ConclusionTo our knowledge this is the first study of its kind in Panama and one of the only ones in the region. The study seeks to generate data that could be shared and applied for future research or clinical practice regarding teleneuropsychological assessments with older adults with similar cohorts.
miR-217-5p NanomiRs Inhibit Glioblastoma Growth and Enhance Effects of Ionizing Radiation via EZH2 Inhibition and Epigenetic Reprogramming
Korleski, Jack , Sudhir, Sweta , Rui, Yuan , Caputo, Christopher , Johnson, Amanda , Madhvacharyula, Tanmaya, Rasamsetty, Anisha, Li, Yunqing , Lal, Bachchu, Zhou, Weiqiang , Smith-Connor, Karen, Tzeng, Stephany Y. , Laterra, John , López-Bertoni, Hernando , Johnson, Amanda L , Li, Yunqing , Zhou, Weiqiang , Tzeng, Stephany Y , Lopez-Bertoni, Hernando , Korleski, Jack , Sall, Sophie , Khela, Harmon Singh , Green, Jordan J.

Mayo Clinic

Cancers | January 1, 2025 | Volume: 17 | Issue: 1 | Pages: 80

10.3390/cancers17010080 | PMID 39796709 Get It

Background/Objectives: CSCs are critical drivers of the tumor and stem cell phenotypes of glioblastoma (GBM) cells. Chromatin modifications play a fundamental role in driving a GBM CSC phenotype. The goal of this study is to further our understanding of how stem cell-driving events control changes in chromatin architecture that contribute to the tumor-propagating phenotype of GBM. Methods: We utilized computational analyses to identify a subset of clinically relevant genes that were predicted to be repressed in a Polycomb repressive complex 2 (PRC2)-dependent manner in GBM upon induction of stem cell-driving events. These associations were validated in patient-derived GBM neurosphere models using state-of-the-art molecular techniques to express, silence, and measure microRNA (miRNA) and gene expression changes. Advanced Poly(β-amino ester) nanoparticle formulations (PBAEs) were used to deliver miRNAs in vivo to orthotopic human GBM tumor models. Results: We show that glioma stem cell (GSC) formation and tumor propagation involve the crosstalk between multiple epigenetic mechanisms, resulting in the repression of the miRNAs that regulate PRC2 function and histone H3 lysine 27 tri-methylation (H3K27me3). We also identified miR-217-5p as an EZH2 regulator repressed in GSCs and showed that miR-217-5p reconstitution using advanced nanoparticle formulations re-activates the PRC2-repressed genes, inhibits GSC formation, impairs tumor growth, and enhances the effects of ionizing radiation in an orthotopic model of GBM. Conclusions: These findings suggest that inhibiting PRC2 function by targeting EZH2 with miR-217-5p advanced nanoparticle formulations could have a therapeutic benefit in GBM.
Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis
Katz, Philip O. , DeVault, Kenneth R. , Metz, David C., Tamene, David, Smith, Neila, Hunt, Barbara, Katz, Philip , Howden, Colin W. , Chang, Yu‐Ming , Spechler, Stuart Jon

Mayo Clinic

Alimentary Pharmacology & Therapeutics | December 25, 2024 | Volume: 61 | Issue: 5 | Pages: 835-851

10.1111/apt.18458 | PMID 39720884 Get It

ABSTRACT Background Patients with erosive oesophagitis, and those with persistent symptomatic non‐erosive gastro‐oesophageal reflux disease, require long‐term maintenance treatment with acid‐suppressing agents. Aim To evaluate the safety of vonoprazan, a potassium‐competitive acid blocker, in an integrated analysis of data from clinical trials in adults. Methods We included 14 clinical trials of vonoprazan conducted in multiple countries. Mean duration of exposure in person‐years to vonoprazan ( n = 5318) was 2068, to comparators lansoprazole ( n = 1925) or esomeprazole ( n = 86) was 751, and to placebo ( n = 779) was 59. We report adverse events, serum gastrin, and liver enzyme levels as the main outcomes. Post‐marketing safety data from December 26, 2014 (date of commercialisation in Japan) to December 25, 2023, are also provided. Results Nasopharyngitis was the only adverse event reported by at least 5.0% of patients (6.94% vonoprazan, 5.07% proton pump inhibitor (PPI), 4.49% placebo). Incidence rates per 100 person‐years for serious adverse events were 10.39 for vonoprazan, 10.65 for PPIs, and 1.69 for placebo. One patient each on vonoprazan and lansoprazole was diagnosed with gastric cancer. Mean serum gastrin levels were higher on vonoprazan than lansoprazole but normalised by 4 weeks after discontinuation. Elevated liver enzyme levels were infrequent and of low magnitude with no differences between vonoprazan and PPIs. There were four deaths; none was considered related to study drug. Conclusions Vonoprazan was well tolerated. Its safety profile from both clinical trial and post‐marketing data were consistent and comparable to that of its PPI comparators with respect to treatment‐emergent adverse events.
Managing the work of living with heart failure: a qualitative study using the cumulative complexity model from Southeastern Minnesota
Smith, Jamie, Shippee, Nathan D. , Finnie, Dawn, Killian, Jill M. , Redfield, Margaret M. , Dunlay, Shannon M. , Dunlay, Shannon , Smith, Jamie L , Shippee, Nathan , Finnie, Dawn M., Montori, Víctor M.

Mayo Clinic

BMJ Open | December 24, 2024 | Volume: 14 | Issue: 12 | Pages: e088127

10.1136/bmjopen-2024-088127 | PMID 39806638 Get It

Objective Patients with heart failure (HF) perform a variety of self-care activities to control symptoms and minimise the risk of HF decompensations. The objective of this study was to understand how patients build capacity and manage the work of living with HF. Design A qualitative study using semi-structured telephone interviews. The interview guide was informed by the Cumulative Complexity Model, a conceptual framework that focuses on a patient’s workload and their capacity to manage that work. Interview transcripts were analysed using a mixed inductive and deductive coding approach with organisation into larger thematic categories. Setting Southeastern Minnesota USA (11 counties) with capture of data from local community healthcare providers under the auspices of the Rochester Epidemiology Project. Participants Intentional sampling of local patients with HF (n=24, median age 69.5 years, 54% women, 63% rural, 54% preserved ejection fraction) who reported high treatment burden and/ or poor health status on a questionnaire. Results Three major themes emerged: using capacity to manage workload, disruptions resulting in workload exceeding capacity and regaining workload-capacity balance. Participants described routinising the daily tasks associated with living with HF to minimise the associated burden and identified disruptions to their routines, including hospitalisations, emergency room visits, worsening health status and changes in healthcare access. To accommodate disruptions and regain workload-capacity balance, participants decreased workload and/or transferred tasks to others to maximise capacity. Conclusions Participants with HF described managing patient workload in times of stable health, but they sometimes struggled to accommodate disruptions and worsening health status. These findings can inform the design of interventions to minimise workload, maximise capacity and improve quality of life for patients with HF.